Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
作者： Karsten Nordhoff , Ute Bank , Frank Striggow , Michael Taeger , Siegfried Ansorge
DOI:
关键词: Medicine 、 Allergy 、 Psoriasis 、 Acne 、 Immune system 、 Peptidase Inhibitors 、 Pharmacology 、 Immunology
摘要: The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. further the use of at least one such substance or pharmaceutical cosmetic composition containing a for preventing and treating diseases, especially diseases with an overshooting immune response (autoimmune allergies, transplant rejections), other chronic inflammatory neuronal brain damages, skin (acne psoriasis, among others), tumor special viral infections (including SARS).
lens.org参考文章(11)
Dirk Reinhold, Frank Buehling, Stefan Brocke, Siegfried Ansorge, Klaus Neubert, Marco Arndt, Uwe Lendeckel, Combinations of enzyme inhibitor-containing preparations and the use thereof ,(2001)
Janine Tadje, Siegfried Ansorge, Uwe Lendeckel, Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors ,(2003)
Dirk Reinhold, Robert Vetter, Harald Gollnick, Siegfried Ansorge, Klaus Neubert, Uwe Lendeckel, Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo ,(2001)
Bradford G. Crandall, Ralph W. Emerson, Use of saponin in methods and compositions for pathogen control ,(1995)
Andre Tartar, David Michael Evans, Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents ,(2002)
Klaus Reymann, Thilo Kahne, Frank Striggow, Siegfried Ansorge, Klaus Neubert, Uwe Lendeckel, Use of enzyme inhibitors of the dipeptidypeptidase iv (ec3.3.14.5) in addition to the aminopeptidase n (ec 3.4.11.2), individually or in a combination thereof, and pharmaceutical preparations thereof for the prevention and/or therapy of ischaemia-caused acute and chronic neurodegenerative process and illnesses, for example ,(2001)
William W. Bachovchin, Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes ,(2002)
Elke Langkopf, Ralf R.H. Lotz, Matthias Eckhardt, Frank Himmelsbach, Michael Mark, Roland Maier, Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions ,(2003)
Robert Vetter, Klaus Neubert, Harald Gollnick, Uwe Lendeckel, Christos C. Zouboulis, Dirk Reinhold, Siegfried Ansorge, Jürgen Faust, Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states ,(2003)